25I-NBOMe (2C-I-NBOMe, Cimbi-5, also shortened to “25I“) is a synthetic hallucinogen that is used in biochemistry research for mapping the brain’s usage of the type 2A serotonin receptor; it is also sometimes used for recreational purposes. A derivative of the substituted phenethylamine 2C-I family, it is the most well-known member of the 25-NB family. It was discovered in 2003 by chemist Ralf Heim at the Free University of Berlin, who published his findings in his PhD dissertation . The compound was subsequently investigated by a team at Purdue University led by David Nichols nbome n bomb mbome nbome drug 25i.
labelled version of 25I-NBOMe, [11C]Cimbi-5, was synthesized and validated as a radiotracer for positron emission tomography (PET) in Copenhagen. Being the first 5-HT2A receptor full agonist PET radioligand, [11C]-CIMBI-5 shows promise as a more functional marker of these receptors, particularly in their high affinity states.
Although 25I-NBOMe was discovered in 2003, it did not emerge as a common recreational drug until 2010, when it was first sold by vendors specializing in the supply of designer drugs. In a slang context, the name of the compound is often shortened to “25I” or is simply called “N-Bomb”. According to a 2014 survey, 25I-NBOMe was the most frequently used of the NBOMe series. By 2013, case reports of 25I-NBOMe intoxication, with and without analytic confirmation of the drug in the body, were becoming increasingly common in the medical literature.
25I-NBOMe is widely rumored to be orally inactive; however, apparent overdoses have occurred via oral administration. Common routes of administration include sublingual, buccal, and intranasal. For sublingual and buccal administration, 25I-NBOMe is often applied to sheets of blotter paper of which small portions (tabs) are held in the mouth to allow absorption through the oral mucosa. There are reports of intravenous injection of 25I-NBOMe solution and smoking the drug in powdered form.
Due to its potency and much lower cost than so-called classical or traditional psychedelics, 25I-NBOMe blotters are sometimes misrepresented as, or mistaken for, LSD blotters. Even small quantities of 25I-NBOMe can produce a large number of blotters. Vendors would import 25I-NBOMe in bulk (E.G 1 kilogram containers) and resell individual doses for a considerable profit.
25I-NBOMe is potent, being active in sub-milligram doses. A common dose of the hydrochloride salt is 600–1,200 µg. The UK Advisory Council on the Misuse of Drugs states that a common dose is between 50 and 100 µg, although other sources indicate that these figures are incorrect; Erowid tentatively suggests that the threshold dosage for humans is 50–250 µg, with a light dose between 200–600 µg, a common dose at 500–800 µg, and a strong dose at 700–1500 µg. At this level of potency, it is not possible to accurately measure a single dose of 25I-NBOMe powder without an analytical balance, and attempting to do so may put the user at significant risk of overdose nbome, 25i-nbome, 25i nbome, n bomb, mbome, nbome drug, 25i .
25I-NBOMe effects usually last 6–10 hours if taken sublingually, orally (or on top of your tongue), or buccally (between your gum and your cheek). When it is ingested, effects usually last 4–6 hours. However, effects can last significantly longer depending on dosage; durations longer than 12 hours have been reported.
25I-NBOMe can also be vaporized and inhaled, this may cause significantly quicker effects and shorter duration as is expected from that route of administration. However, this route of administration is very dangerous, unless using precise liquid measurement, due to the difficulties of measuring and handling substances active in the microgram range.
25I-NBOMe has similar effects to LSD, though users report more negative effects while under the influence and more risk of harm following use as compared to the classical psychedelics.
Case reports of seven British males who presented to an emergency room following analytically confirmed 25I-NBOMe intoxication suggest the following potential adverse effects: “tachycardia (n = 7), hypertension (4), agitation (6), aggression, visual and auditory hallucinations (6), seizures (3), hyperpyrexia (3), clonus (2), elevated white cell count (2), elevated creatine kinase (7), metabolic acidosis (3), and acute kidney injury (1).”
Recreational use of 25I-NBOMe carries a significant risk of both pharmacological and behavioral toxicity. 25I-NBOMe is a relatively new substance, and little is known about its pharmacological risks or its interaction with other substances. The LD50 has not yet been determined. It is a highly potent serotonin agonist and, due to its psychedelic effects and ambiguous legal status, a designer drug with reports of recreational use beginning in 2010. Reports of deaths and significant injuries have been attributed to the use of 25I-NBOMe, prompting some governments to control its possession, production, and sale. The website Erowid states that 25I-NBOMe is extremely potent and should not be snorted as this method of administration “appears to have led to several deaths in the past year.” Several non-fatal overdoses requiring prolonged hospitalization have also been reported.
As of August 2015, 25I-NBOMe has reportedly led to at least 19 overdose deaths in the United States. In June 2012, two teens in Grand Forks, North Dakota and East Grand Forks, Minnesota fatally overdosed on a substance that was allegedly 25I-NBOMe, resulting in lengthy sentences for two of the parties involved and a Federal indictment against the Texas-based online vendor. A 21-year-old man from Little Rock, Arkansas died in October 2012 after taking a liquid drop of the drug nasally at a music festival. He was reported to have consumed caffeinated alcoholic beverages for “several hours” beforehand. It is unclear what other drugs he may have consumed, as autopsies generally do not test for the presence of research chemicals. In January 2013, an 18-year-old in Scottsdale, Arizona, died after consuming 25I-NBOMe sold as LSD; a toxicology screening found no other drugs in the person’s system. The drug is the suspected cause of death in another Scottsdale, Arizona, incident in April 2013. It is also cited in the death of a 21-year-old woman in August 2013 and the death of a 17-year-old in Minnesota in January 2014, as well as the death of a 15-year old in Washington in September 2014.
25I-NBOMe has been implicated in multiple deaths in Australia. In March 2012, a man in Australia died from injuries sustained by running into trees and power poles while intoxicated by 25I-NBOMe. A Sydney teenager jumped to his death on June 5, 2013. He reportedly jumped off a balcony thinking he could fly.
25I-NBOMe has been linked to a major case on January 20, 2016 in Cork, Republic of Ireland, which left six teenagers hospitalized, one of whom later died. At least one of the teenagers suffered a cardiac arrest, according to reports, along with extreme internal bleeding nbome 25i-nbome n bomb mbome nbome drug 25i .
25I-NBOMe presumably exhibits functional selectivity at the 5HT2A receptor similar to other phenethylamine hallucinogens, activating the Phospholipase A2 signal cascade, which is responsible for the release of Thromboxane A2, triggering blood platelet aggregation. Excessive concentrations of TXA2 could lead to thrombosis, which when coupled with 25I-NBOMe’s vasoconstrictive effect, is a major risk factor for cardiac ischemia, a dangerous condition the symptoms of which are present in several toxicological reports.
25I-NBOMe acts as a highly potent full agonist for the human 5-HT2A receptor with a dissociation constant (Ki) of 0.044 nM, making it some sixteen times the potency of 2C-I itself at this receptor. A radiolabelled form of 25I-NBOMe can be used for mapping the distribution of 5-HT2A receptors in the brain.
25I-NBOMe induces a head-twitch response in mice which is blocked completely by a selective 5-HT2A antagonist, suggesting its psychedelic effects are mediated by 5-HT2A. This study suggested that 25I-NBOMe is approximately 14-fold more potent than 2C-I in-vivo.
While in-vitro studies showed that N-benzyl derivatives of 2C-I were significantly increased in potency compared to 2C-I, the N-benzyl derivatives of the related compound DOI were inactive. NBOMe effects are similar to LSD. In small doses you can experience strong visual hallucinations whether eyes are open or closed, and feel euphoric, empathetic, altered consciousness, and love. These feelings can occur at the same time as dizziness, hot and/or cold flushes, increased perspiration, and numbness in the arms and legs. NBOMe has a quick onset with an initial rush and then strong psychedelic effects that typically last 4-8 hours.
NBOMe should be avoided. It is very potent and a small amount can result in an overdose. It is important not to use alone and to have access to a phone.
Do not snort NBOMe, taking is this way has been associated with hospitalisations and death.
The deaths associated with NBOMe have mostly been accidental overdoses. This is because it is very hard to get an accurate dose. Any amount greater than 500 micrograms (half a milligram) is known to be dangerous. If you plan to use it then keep your doses small – no more than one tab or 200 micrograms of liquid. As a comparison, a typical line of cocaine is 100 milligrams, which is 200 times the 500 microgram amount. It is very easy for someone estimating NBOMe doses to get this wrong and take too much.
NBOMe can usually be distinguished from LSD by its bitter and metallic taste. Unlike LSD it numbs the gums and tongue.
Mixing drugs is always risky. NBOMe is a powerful psychedelic and not much is known about its interaction with other substances. It is strongly recommended to not mix NBOMe with other drugs. See our Drug interactions section for more about the effects of mixing NBOMe with other drugs.
- Stimulation – In terms of its effects on the physical energy levels of the user, 25I-NBOMe is usually considered to be very energetic and stimulating. For most people, this substance induces a unique type of physical stimulation which can be described as feeling extremely energetic but in a way which does not force the tripper to move unless they genuinely choose to do so. For others, however, the stimulation can be quite uncontrollable, occasionally resulting in bodily shakes and a grinding of the teeth comparable to that of MDMA and traditional stimulants such as amphetamine.
- Perception of bodily lightness – In terms of the body’s perceived weight, this substance consistently leaves people feeling extremely light, often to the point of total weightlessness.
- Spontaneous physical sensations – The “body high” itself can be described as a mild, all-encompassing, soft but euphoric tingling sensation. This tingling sensation is also accompanied by spontaneous rushes of euphoria that become longer and more drawn out proportional to the dosage consumed.
- Mouth numbing – Assuming the substance has been taken sublingually, the very first physical effect which a person will notice immediately after sublingual absorption is a strong, unpleasant metallic chemical taste. This is accompanied by a very distinct feeling of general numbness of the tongue and mouth which can stay for up to an hour after the blotter paper has been consumed.
- Nausea – As the user begins to come up, nausea is not uncommon and can sometimes result in initial vomiting, although nausea usually disappears when the user has vomited or the trip fully set in. In comparison to other psychedelics such as psilocin, 2C-E and 2C-I, this could actually be considered very mild in its intensity.
- Temperature regulation suppression
- Increased bodily temperature
- Abnormal heartbeat
- Increased heart rate
- Increased blood pressure
- Muscle contractions
- Muscle cramps
- Muscle tension
- Gustatory hallucination
- Appetite suppression
- Stomach cramps
- Dry mouth
- Difficulty urinating or Frequent urination
- Restless legs
- Pupil dilation